Want to see AU:EMV full AI Analyst Report?
Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$1.50
▼(-12.79% Downside)
Action:Reiterated
Date:08/26/26
The score is primarily constrained by weak financial performance: zero revenue in 2026, sustained losses, and ongoing free cash flow burn. Technicals are a partial offset, with the share price above major moving averages and positive MACD indicating constructive momentum. Valuation remains a secondary drag because negative earnings (negative P/E) reduces the usefulness of traditional valuation signals and no dividend yield is available.
Positive Factors
Point-of-care imaging opportunity
EMvision is developing a portable imaging platform aimed at urgent neurological assessment in emergency, hospital, remote, and resource-limited settings. If development succeeds, this broad use case could support multiple care environments and create a durable pathway for adoption beyond conventional imaging suites.
Negative Factors
Revenue collapse
The move from strong revenue in 2022–2024 to zero revenue in 2026 demonstrates severe commercial instability and makes the current business model difficult to assess from operating results. Without recurring revenue, funding product development and converting the technology into a sustainable business remain significant challenges.
Read all positive and negative factors
Positive Factors
Negative Factors
Point-of-care imaging opportunity
EMvision is developing a portable imaging platform aimed at urgent neurological assessment in emergency, hospital, remote, and resource-limited settings. If development succeeds, this broad use case could support multiple care environments and create a durable pathway for adoption beyond conventional imaging suites.
Read all positive factors
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$139.43M
Dividend YieldN/A
Average Volume (3M)33.01K
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue GrowthN/A
EPS Growth20.40%
CountryAU
Employees46
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.09
Shares Outstanding92,955,560
10 Day Avg. Volume34,829
30 Day Avg. Volume33,010
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)8.78
Price to Sales (P/S)0.00
P/FCF Ratio-21.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside83.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.13
Revenue Forecast (FY)AU$5.00M
EMvision Medical Devices Ltd. Business Overview & Revenue Model
Company Description
EMVision Medical Devices Limited is an Australian enterprise specializing in the innovation, development, and market introduction of advanced imaging and diagnostic healthcare technologies. The company's principal offering is a compact, mobile bra...
EMvision Medical Devices Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 5.05M | 11.22M | 6.97M | 4.36M |
| Gross Profit | -416.90K | 5.05M | 11.22M | 6.63M | 4.12M |
| EBITDA | -16.51M | -8.44M | -8.35M | -5.99M | -7.84M |
| Net Income | -8.32M | -9.81M | -2.73M | -3.87M | -6.11M |
Balance Sheet | |||||
| Total Assets | 23.04M | 15.57M | 23.97M | 11.52M | 8.51M |
| Cash, Cash Equivalents and Short-Term Investments | 17.10M | 10.53M | 18.67M | 9.97M | 6.80M |
| Total Debt | 3.41M | 3.53M | 2.90M | 3.04M | 737.86K |
| Total Liabilities | 7.27M | 6.29M | 5.46M | 6.40M | 1.43M |
| Stockholders Equity | 15.77M | 9.28M | 18.52M | 5.12M | 7.08M |
Cash Flow | |||||
| Free Cash Flow | -6.37M | -7.89M | -6.29M | 646.86K | -3.97M |
| Operating Cash Flow | -6.25M | -7.84M | -5.99M | 834.15K | -3.78M |
| Investing Cash Flow | -124.22K | -50.37K | -302.41K | -187.29K | -191.12K |
| Financing Cash Flow | 13.02M | -258.34K | 15.00M | 2.52M | 1.08M |
EMvision Medical Devices Ltd. Technical Analysis
Negative
1.72
Price Trends
1.68
Negative
1.63
Negative
1.68
Negative
Market Momentum
-0.04
Positive
40.48
Neutral
35.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMV, the sentiment is Negative. The current price of 1.72 is above the 20-day moving average (MA) of 1.58, above the 50-day MA of 1.68, and above the 200-day MA of 1.68, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 40.48 is Neutral, neither overbought nor oversold. The STOCH value of 35.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EMV.
EMvision Medical Devices Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$45.95M | 209.09 | 0.93% | ― | 18.54% | ― | |
55 Neutral | AU$2.07B | -8.70 | -288.42% | ― | 20.64% | -457.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$139.43M | -16.54 | -46.84% | ― | ― | 20.40% | |
47 Neutral | AU$29.09M | -4.09 | -201.54% | ― | -100.00% | 50.49% | |
42 Neutral | AU$26.66M | -2.53 | -103.48% | ― | -22.43% | 15.02% | |
41 Neutral | AU$46.52M | -2.38 | -62.14% | 0.64% | 12.05% | -31.71% |
* Healthcare Sector Average
AU:EMV
EMvision Medical Devices Ltd.
1.50
-0.26
-14.77%
AU:CMP
Compumedics Limited
0.23
-0.11
-31.34%
AU:NTI
Neurotech International
0.02
<0.01
12.50%
AU:CYC
Cyclopharm Limited
0.37
-0.27
-42.19%
AU:CBL
Control Bionics Ltd.
0.05
0.02
44.12%
AU:4DX
4DMedical Ltd
3.43
1.60
87.43%
EMvision Medical Devices Ltd. Corporate Events
EMVision advances stroke imaging trials and pre-hospital rollout while bolstering cash reserves
Oct 25, 2026
EMVision reported strong progress in its clinical and product development programs during the quarter to 30 September 2026, as recruitment in the pivotal validation trial for the emu™ in-hospital brain scanner surpassed 230 patients by early...
EMVision Sets November Date for 2026 Annual General Meeting
Oct 22, 2026
EMVision Medical Devices Ltd has called its 2026 Annual General Meeting of shareholders to be held in person at its Macquarie Park, Sydney offices on 24 November 2026 at 2:00pm AEDT. The company has made the notice of meeting, explanatory memorand...
EMVision’s emu Brain Scanner Gains Traction in Mayo Clinic Stroke Trial
Oct 19, 2026
Mayo Clinic Florida has begun integrating EMVision’s investigational emu portable radiofrequency brain scanner into its emergency code stroke workflow as part of a pivotal validation trial. The device is being used on adults presenting with ...
EMvision Sets November Date and Nomination Deadline for 2026 AGM
Sep 28, 2026
EMvision Medical Devices has scheduled its Annual General Meeting for 24 November 2026 at its Sydney office in Macquarie Park, with full details of the meeting and proposed resolutions to be provided to shareholders in advance and made available o...
EMVision Secures $4.3m R&D Tax Refund to Advance Stroke Diagnostic Devices
Sep 27, 2026
EMVision Medical Devices has received a $4.3 million cash refund under Australia’s RD Tax Incentive program for eligible FY2026 activities, bolstering non-dilutive funding alongside a previously reported $17.1 million cash balance and $4.6 m...
EMVision advances portable stroke scanner with successful mobile trial and new funding
Sep 15, 2026
EMVision has completed Stage 1 of its feasibility study for the First Responder portable brain scanner with Melbourne’s Mobile Stroke Unit, demonstrating successful usability and workflow in real-world pre-hospital environments. The advanced...
EMvision Issues New Performance Rights Under Employee Incentive Scheme
Sep 11, 2026
EMvision Medical Devices Ltd. has notified the market of the issue of 272,617 new performance rights expiring on June 30, 2031. These unquoted securities form part of an employee incentive scheme and are not intended to be listed on the ASX.The is...
EMVision advances regional stroke study to support bedside scanner rollout
Sep 2, 2026
EMVision Medical Devices is advancing preparations for its CRC-P funded Regional Benefits Study, which will test the emu™ bedside brain scanner in regional South Australian hospitals that currently lack on-site CT imaging. The study aims to ...
EMVision passes 200-patient milestone in pivotal stroke imaging trial
Aug 30, 2026
EMVision Medical Devices has passed 200 patients enrolled in its emu™ Pivotal (Validation) Trial, marking a key milestone as the bedside brain scanner is integrated into “code stroke” pathways at major U.S. and Australian hospita...
EMVision updates registered office without operational changes
Aug 23, 2026
EMVision Medical Devices Ltd has updated its registered office address to Suite 4.01, 65 Epping Road, Macquarie Park, NSW 2113, effective immediately. The company emphasised that its principal place of business and all other contact details remain...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.